Prediction of major adverse cardiovascular events in patients with acute coronary syndrome: Development and validation of a non-invasive nomogram model based on autonomic nervous system assessment

Jun Wang1,2,3,4,5,6†, Xiaolin Wu8†, Ji Sun1,2,3,4,5,6†, Tianyou Xu1,2,3,4,5,6†, Tongjian Zhu8, Fu Yu1,2,3,4,5,6, Shoupeng Duan1,2,3,4,5,6, Qiang Deng1,2,3,4,5,6, Zhihao Liu1,2,3,4,5,6, Fuding Guo1,2,3,4,5,6†, Xujun Li1,2,3,4,5,6, Yijun Wang1,2,3,4,5,6, Lingpeng Song1,2,3,4,5,6, Hui Feng7*, Xiaoya Zhou1,2,3,4,5,6* and Hong Jiang1,2,3,4,5,6*

1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China, 2Cardiac Autonomic Nervous System Research Center of Wuhan University, Wuhan, China, 3Cardiovascular Research Institute, Wuhan University, Wuhan, China, 4Hubei Key Laboratory of Cardiovascular Diseases, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China

Background: Disruption of the autonomic nervous system (ANS) can lead to acute coronary syndrome (ACS). We developed a nomogram model using heart rate variability (HRV) and other data to predict major adverse cardiovascular events (MACEs) following emergency coronary angiography in patients with ACS.

Methods: ACS patients admitted from January 2018 to June 2020 were examined. Holter monitors were used to collect HRV data for 24 h. Coronary angiograms, clinical data, and MACEs were recorded. A nomogram was developed using the results of Cox regression analysis.

Results: There were 439 patients in a development cohort and 241 in a validation cohort, and the mean follow-up time was 22.80 months. The nomogram considered low-frequency/high-frequency ratio, age, diabetes, previous myocardial infarction, and current smoking. The area-under-the-curve (AUC) values for 1-year MACE-free survival were 0.790 (95% CI: 0.702–0.877) in the development cohort and 0.894 (95% CI: 0.820–0.967) in the external validation cohort. The AUCs for 2-year MACE-free survival were 0.802 (95% CI: 0.739–0.866) in the development cohort and 0.798...
Wang et al. 10.3389/fcvm.2022.1053470

(95% CI: 0.693–0.902) in the external validation cohort. Development and validation were adequately calibrated and their predictions correlated with the observed outcome. Decision curve analysis (DCA) showed the model had good discriminative ability in predicting MACEs.

**Conclusion:** Our validated nomogram was based on non-invasive ANS assessment and traditional risk factors, and indicated reliable prediction of MACEs in patients with ACS. This approach has potential for use as a method for non-invasive monitoring of health that enables provision of individualized treatment strategies.

**KEYWORDS**

acute coronary syndrome, major adverse cardiovascular events, nomogram, prediction nomogram, outcomes, autonomic nervous system

**Introduction**

Coronary artery disease (CAD) is the major cause of death worldwide (1, 2). Even though risk-factor targeted management and revascularization have dramatically improved the outcomes for these patients, especially those with acute coronary syndrome (ACS), these patients remain at high risk for morbidity and mortality (3–5). Strategies for risk stratification and risk-adjusted management of ACS have been a major focus of researchers during the past decade (6, 7). Therefore, timely diagnosis, early treatment, and early detection of risk factors have great clinical significance in cardiovascular care (6, 7). Notably, remote monitoring of cardiovascular health has received a great deal of attention for management of patients with cardiovascular disease (8).

During pathological conditions, there is evidence that disruption of the autonomic nervous system (ANS) potentially affects the growth of atherosclerotic plaques, and these findings have significant prognostic implications for patients with ACS (9–11). In clinical settings, non-invasive and ambulatory monitoring techniques that measure heart rate variability (HRV) provide insight into autonomic modulation of cardiac function (12). Moreover, due to its value as an independent prognostic indicator, measurements of HRV have potential use in clinical evaluations and risk stratification of high risk patients (12). Novel and effective digital monitoring risk-assessment tools that are used to monitor general health status should be simple, easy-to-learn, and easy for patients to operate.

A previous report showed that risk stratification using an objective and non-invasive electrocardiogram and a HRV-based tool for 1 month reduced adverse clinical outcomes and improved myocardial infarct score more than thrombolysis, although this study did not perform validation using an external cohort (13). In addition, there are several well-established models for determining the risk of cardiovascular diseases in United States and Europe, but these have generally not assessed the ANS (14). Moreover, the development of risk prediction models and recommendations regarding risk assessment in clinical guidelines has rarely been reviewed from a global perspective.

Therefore, the current study used a systematic and integrated approach that incorporated HRV data with classical risk factors to develop a prognostic model that accurately and non-invasively predicts outcomes in patients with ACS who received emergency coronary angiography.

**Materials and methods**

**Patient population**

The derivation set consisted of 439 consecutive patients who had ACS and received emergency coronary angiography and successful Holter monitoring for 24 h at Renmin Hospital of Wuhan University from January 2018 to June 2020. The validation set consisted of 241 consecutive patients who had ACS and received emergency coronary angiography and successful Holter monitoring for 24 h at Xiangyang Central Hospital from January 2018 to June 2020 (Figure 1). International guidelines were used to diagnose ACS (15). Patients with the following conditions were excluded: chronic coronary syndromes, delay in coronary angiography due to valvular heart disease, congenital heart disease, pacemaker implantation, paroxysmal or atrial fibrillation, chronic or acute phases of inflammation, malignant tumor, or lack of 24-h ambulatory HRV monitoring. Ethical approval was granted for the study by the local ethics committee (Renmin Hospital of Wuhan University; No. WDRY2022-K075; Xiangyang Central Hospital; No.2022-066), which waived the need for patient consent.
Biochemical tests

Prior to emergency coronary angiography, blood biomarkers of inflammation [neutrophils, lymphocytes, neutrophil to lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR)], kidney function [serum creatinine, uric acid, and estimated glomerular filtration rate (eGFR)] and glucose were measured. Blood was collected in the early morning after fasting to determine the lipid profile [high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol [TC], triglyceride [TG], and lipoprotein a [Lp (a)]].

Holter monitoring

As previously described, each patient underwent Holter monitoring for 24 h after angiography to evaluate the ANS by analysis of 24-h mean heart rate and variables of HRV (16–18). An average 5-min short-term HRV analysis was conducted. R peak detection was used to identify normal sinus RR intervals (SDNN), and the standard deviation of all normal SDNN, root mean square successive difference (RMSSD), and standard deviation average of NN intervals (SDANN) were then calculated. The percentage of the time that the difference between adjacent normal RR intervals was greater than 50 ms over the total number of NN intervals (PNN50) was also calculated. For power spectrum analysis of HRV, the high-frequency (HF) spectrum ranged from 0.15 to 0.4 Hz; the low-frequency (LF) spectrum ranged from 0.04 to 0.15 Hz; and the very low-frequency (VLF) spectrum ranged from 0.003 to 0.04 Hz. Normalized units of the LF band (nLF) were calculated as: $100 \times \frac{\text{LF}}{(\text{total power} - \text{VLF})}$; normalized units of the HF band (HFn) were calculated as: $100 \times \frac{\text{HF}}{(\text{total power} - \text{VLF})}$; the ratio of the two values was calculated as: LF/HF.

Coronary angiography

Coronary angiography was performed immediately after admission for ACS by experienced senior cardiologists who used standard treatment protocols. In accordance with guidelines, loading doses of aspirin, ticagrelor, or clopidogrel were given to patients with ACS and before operation (15). The percutaneous coronary intervention (PCI) procedures were performed by a team of highly experienced senior physicians in accordance with each patient’s coronary anatomy and clinical condition. After the procedure, each patient received standard treatment regimens based on guideline recommendations, including modern antiplatelet therapy and standard-intensity statins, and received regular follow-up at the clinic after discharge.
| Characteristic or outcome | Development cohort ($n = 439$) | Validation cohort ($n = 241$) | $T$, $Z$, or $\chi^2$ | $P$ |
|--------------------------|-------------------------------|--------------------------------|----------------------|-----|
| Male, $n$ (%)            | 270 (61.5)                    | 153 (63.5)                    | 0.260                | 0.610 |
| Age, years               | 63.32 ± 10.56                 | 62.33 ± 11.08                 | 1.148                | 0.251 |
| Hypertension, $n$ (%)    | 277 (63.1)                    | 141 (58.5)                    | 1.385                | 0.239 |
| Duration of Hypertension, years | 10.00 (5.00, 23.00) | 10.00 (5.00, 23.00) | 0.958                | 0.338 |
| Diabetes, $n$ (%)        | 105 (24.0)                    | 47 (19.5)                     | 1.757                | 0.185 |
| Duration of diabetes, years | 7.00 (3.00,10.00)             | 10.00 (5.00,14.00)            | 1.685                | 0.092 |
| Current smoker, $n$ (%)  | 148 (33.7)                    | 94 (39.0)                     | 1.900                | 0.168 |
| Current drinker, $n$ (%) | 84 (19.1)                     | 59 (24.5)                     | 2.678                | 0.102 |
| Family history of hypertension, $n$ (%) | 34 (7.7) | 14 (5.8) | 0.889                | 0.346 |
| Family history of CAD, $n$ (%) | 28 (6.4) | 15 (6.2) | 0.006                | 0.937 |
| Family history of diabetes, $n$ (%) | 34 (7.7) | 19 (7.9) | 0.004                | 0.948 |
| Previous PCI, $n$ (%)    | 128 (29.2)                    | 74 (30.7)                     | 0.179                | 0.673 |
| Previous myocardial infarction, $n$ (%) | 49 (11.2) | 27 (11.2) | 0.000                | 0.987 |
| Neutrophils ($\times 10^9$L) | 3.98 (2.98, 5.46) | 4.55 (2.80, 6.40) | 1.561                | 0.119 |
| Lymphocytes ($\times 10^9$L) | 1.64 (1.27,2.16) | 1.58 (1.20, 2.27) | 0.290                | 0.772 |
| NLR                      | 2.33 (1.72, 3.57)             | 2.60 (1.42, 4.24)             | 0.216                | 0.829 |
| PLT ($\times 10^9$L)     | 208.25 ± 62.20                | 207.51 ± 54.33                | 0.154                | 0.878 |
| PLR                      | 125.52 (92.27, 160.00)        | 122.50 (85.27, 181.58)        | 0.111                | 0.912 |
| eGFR, mL/min/1.73 m²     | 87.56 ± 20.30                 | 84.95 ± 18.43                 | 1.659                | 0.098 |
| Creatinine, $\mu$ mol/L  | 72.54 ± 22.41                 | 75.93 ± 23.11                 | 1.865                | 0.063 |
| Uric acid, mmol/L        | 365.78 ± 114.15               | 350.97 ± 99.04                | 1.694                | 0.091 |
| Glucose, mmol/L          | 6.48 ± 2.85                   | 6.64 ± 2.59                   | 0.719                | 0.473 |
| TG, mmol/L               | 1.44 (1.03, 2.06)             | 1.35 (0.96, 2.02)             | 1.582                | 0.114 |
| TC, mmol/L               | 4.22 ± 1.12                   | 4.33 ± 1.02                   | 1.298                | 0.195 |
| HDL-C, mmol/L            | 1.09 ± 0.29                   | 1.10 ± 0.28                   | 0.190                | 0.850 |
| LDL-C, mmol/L            | 2.43 ± 0.98                   | 2.67 ± 0.83                   | 3.406                | 0.001 |
| Lp (a), g/L              | 188.00 (78.00, 323.00)        | 196.45 (135.66, 269.91)       | 0.663                | 0.507 |
| Average heart rate, bpm  | 68.96 ± 9.61                  | 67.98 ± 9.30                  | 1.278                | 0.202 |
| SDNN, ms                 | 115.21 ± 33.01                | 114.30 ± 29.25                | 0.358                | 0.720 |
| SDANN, ms                | 77.69 ± 35.68                 | 80.30 ± 29.32                 | 1.026                | 0.305 |
| rMSSD, ms                | 31.00 (22.00, 47.00)          | 23.00 (16.50, 31.50)          | 7.229                | <0.001 |
| Pnn50                    | 5.37 (2.00, 9.00)             | 4.00 (2.00, 6.00)             | 3.621                | <0.001 |
| Normalized LF            | 59.65 ± 15.01                 | 58.66 ± 22.45                 | 0.616                | 0.539 |
| Normalized HF            | 40.31 ± 15.01                 | 41.38 ± 22.50                 | 0.659                | 0.510 |
| LF/HF                    | 1.52 (0.98, 2.36)             | 3.16 (2.00, 4.66)             | 12.381               | <0.001 |
| Clinical Systolic Blood Pressure, mmHg | 134.68 ± 19.83 | 133.04 ± 23.59 | 0.916                | 0.360 |
| Clinical Diastolic Blood Pressure, mmHg | 77.06 ± 12.01 | 78.33 ± 12.16 | 1.316                | 0.189 |
| Heart rate (bpm)         | 76.88 ± 13.38                 | 75.98 ± 16.84                 | 0.762                | 0.446 |
| MACEs, $n$ (%)           | 37 (8.4)                      | 24 (10.0)                     | 0.446                | 0.504 |
| Cardiac death, $n$ (%)   | 9 (2.1)                       | 7 (2.9)                       | 0.494                | 0.482 |
| Revascularization, $n$ (%) | 23 (5.2)                      | 9 (3.7)                       | 0.786                | 0.375 |
| Myocardial infarction, $n$ (%) | 13 (3.0) | 9 (3.7) | 0.297                | 0.586 |

*Values are given as $n$ (%), mean ± SD, or median (IQR).

CAD, coronary artery disease; PCI, percutaneous coronary intervention; NLR, neutrophil to lymphocyte ratio; PLT, platelet counts; PLR, platelet-to-lymphocyte ratio; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; Lp (a), lipoprotein a; SDNN, standard deviation of all normal sinus RR intervals; SDANN, standard deviation average of normal-tonormal (NN) intervals; pNN50, percentage of the number of times that the difference between adjacent normal RR intervals > 50 ms in the total number of NN intervals; rMSSD, root mean square successive difference; LF, low-frequency; HF, high-frequency; MACEs, major adverse cardiovascular events. Bold values represent the $p < 0.05$ statistical significance.
TABLE 2 Univariate and multivariable Cox regression analysis of factors associated with MACEs in the development cohort.

| Variable                                  | Univariate |         | P    |         | Multivariate |         | P    |
|-------------------------------------------|------------|---------|------|---------|--------------|---------|------|
|                                           | HR 95% CI  |         |      |         | HR 95% CI    |         |      |
| Male                                      | 0.768      | 0.386–1.529 | 0.452 |         | 1.043        | 1.004–1.083 | 0.030 |
| Age                                       | 1.054      | 1.019–1.090 | 0.002 |         | 1.043        | 1.004–1.083 | 0.030 |
| Hypertension                              | 1.409      | 0.696–2.851 | 0.341 |         | 2.160        | 1.104–4.225 | 0.024 |
| Diabetes                                  | 2.508      | 1.309–4.806 | 0.006 |         | 2.426        | 1.214–4.849 | 0.012 |
| Current smoker                            | 2.117      | 1.111–4.034 | 0.023 |         |              |         |      |
| Current drinker                           | 0.979      | 0.430–2.228 | 0.959 |         |              |         |      |
| Family history of hypertension            | 0.659      | 0.159–2.740 | 0.566 |         |              |         |      |
| Family history of CAD                     | 0.850      | 0.204–3.534 | 0.823 |         |              |         |      |
| Family history of diabetes mellitus       | 1.018      | 0.313–3.314 | 0.977 |         |              |         |      |
| Previous PCI                              | 0.968      | 0.301–3.112 | 0.956 |         |              |         |      |
| Previous myocardial infarction            | 3.684      | 1.820–7.457 | <0.001 |         | 2.755        | 1.202–6.316 | 0.017 |
| Neutrophils                               | 1.024      | 1.004–1.046 | 0.020 |         | 1.003        | 0.977–1.029 | 0.835 |
| Lymphocytes                               | 1.034      | 0.987–1.083 | 0.156 |         |              |         |      |
| NLR                                        | 0.947      | 0.814–1.101 | 0.477 |         |              |         |      |
| PLT                                        | 0.995      | 0.990–1.001 | 0.079 |         |              |         |      |
| PLR                                        | 0.993      | 0.987–0.999 | 0.019 |         | 0.995        | 0.988–1.001 | 0.104 |
| eGFR                                       | 0.984      | 0.971–0.996 | 0.012 |         | 0.999        | 0.983–1.016 | 0.928 |
| Creatinine                                | 1.011      | 0.999–1.022 | 0.062 |         |              |         |      |
| Uric acid                                 | 0.999      | 0.996–1.002 | 0.533 |         |              |         |      |
| Glucose                                   | 1.007      | 0.904–1.233 | 0.894 |         |              |         |      |
| TG                                         | 0.944      | 0.725–1.229 | 0.668 |         |              |         |      |
| TC                                         | 1.120      | 0.852–1.472 | 0.418 |         |              |         |      |
| HDL-C                                      | 0.793      | 0.254–2.479 | 0.690 |         |              |         |      |
| LDL-C                                      | 1.145      | 0.839–1.561 | 0.393 |         |              |         |      |
| Lp (a)                                     | 1.001      | 1.001–1.003 | 0.005 |         | 1.001        | 0.999–1.002 | 0.096 |
| Average heart rate                        | 0.999      | 0.966–1.034 | 0.970 |         |              |         |      |
| SDNN                                       | 0.995      | 0.985–1.006 | 0.371 |         |              |         |      |
| SDANN                                      | 1.001      | 0.991–1.009 | 0.986 |         |              |         |      |
| rMSSD                                      | 0.997      | 0.987–1.008 | 0.635 |         |              |         |      |
| Pnn50                                      | 0.997      | 0.963–1.032 | 0.851 |         |              |         |      |
| Normalized LF                             | 0.962      | 0.942–0.982 | <0.001 |         |              |         |      |
| Normalized HF                             | 1.040      | 1.019–1.061 | <0.001 |         |              |         |      |
| Normalized LF/HF                          | 0.559      | 0.370–0.844 | 0.006 |         | 0.640        | 0.427–0.960 | 0.031 |
| Clinical systolic blood pressure           | 1.015      | 1.001–1.031 | 0.049 |         | 1.018        | 0.999–1.037 | 0.053 |
| Clinical diastolic blood pressure          | 1.004      | 0.977–1.031 | 0.777 |         |              |         |      |
| Average heart rate                        | 1.003      | 0.980–1.027 | 0.792 |         |              |         |      |

See Table 1. Bold values represent the \( p < 0.05 \) statistical significance.

Follow-up

Follow-up, which consisted of telephone calls and/or clinic visitations, was used to determine when an endpoint occurred. The primary endpoint was a major adverse cardiac events (MACEs), defined as the composite of cardiac mortality, recurrence of myocardial infarction, or need for revascularization. Cardiac mortality refers to death caused by any cardiac condition. Myocardial infarction refers to a new myocardial infarction in targeted or non-targeted vessels. Revascularization refers to targeted or non-targeted vessels.

Statistical analysis

Statistical analysis was conducted using SPSS version 23 (IBM, Chicago, IL) and R software version 3.6.1 (R Foundation for Statistical Computing, Vienna). Means and standard deviations (SDs) were presented for continuous variables with
normal distributions, and medians and interquartile ranges (IQRs) for continuous variables with skewed distributions. For analysis of continuous variables with normal distributions, the $t$-test was used; for analysis of continuous variables with non-normal distributions, the Mann-Whitney $U$-test or the Kruskal-Wallis test was used. Analysis of categorical variables was performed using the $\chi^2$-test. In all comparisons, a $P$-value below 0.05 indicated statistical significance.

Univariate and multivariate analyses were used to identify factors independently associated with outcome (MACEs). Analysis of the statistical significance of each individual variable was performed using univariate analysis. This was followed by multivariate analysis of variables that were significant in the univariate analysis to identify significant and independent predictors of MACEs.

Predictive nomograms were constructed using predictors that were statistically significant. R software was used to construct the nomogram using the Regression Modeling Strategies (rms) package. Risk nomograms were analyzed using receiver characteristic curves (ROC) to assess their ability to discriminate MACEs based on calculation of area under the ROC curve (19). Using the rms package, calibration curves were plotted and calculated to evaluate the calibration of the MACEs after construction of the ACS risk nomograms. Bootstrapping was performed by repeated random sampling (500 times) for internal validation of model accuracy. Decision curve analysis (DCA) was used to quantify the clinical efficacy of the nomograms based on their net benefit for different threshold probabilities (19).

**Results**

**Patient characteristics**

We retrospectively screened 680 patients who had ACS and received emergency angiography and divided them into a development cohort ($n = 439$) and an independent external validation cohort ($n = 241$). Among all 680 patients, the mean age was 62.9 (± 12.6) years-old and 423 patients (62.2%) were males. The two cohorts were well balanced in baseline characteristics and outcomes except for clinical presentation, LDL-C, in-hospital PCI, several results from the coronary angiography, and HRV (Table 1). The overall incidence of MACEs was 9.10% during the median follow-up time of 22.80 months, with similar incidences in the two cohorts.

**Potential predictors of major adverse cardiovascular events**

We used multivariable stepwise Cox regression model to identify significant and independent predictors of MACEs in the development cohort (Table 2). There were five significant and independent predictors of MACEs: age (HR: 1.043, 95% CI:
FIGURE 3
Nomogram for predicting 1 and 2-year MACE-free survival, based on multivariate Cox regression analysis. For each patient, each clinical characteristic was assigned points by drawing a vertical line from its value to the top row. The points for all five characteristics were added to determine total points middle row. Then, the total points were used to determine the 1 and 2-year probabilities of MACE-free survival by drawing a vertical line to the bottom two rows.

1.004–1.083, \(P = 0.030\), diabetes (HR: 2.160, 95% CI: 1.104–4.225, \(P = 0.024\)), current smoker (HR: 2.426, 95% CI: 1.214–4.849, \(P = 0.012\)), previous myocardial infarction (HR: 2.755, 95% CI: 1.202–6.316, \(P = 0.017\)), and LF/HF ratio (HR: 0.640, 95% CI: 0.427–0.960, \(P = 0.031\)) (Figure 2).

Construction of the nomogram

We then used a nomogram model to present the results of the multivariate Cox regression in predicting the 1 and 2-year probability of MACE-free survival (Figure 3). To calculate risk for a patient using this nomogram model, a vertical line is first drawn from the value of each of the five parameters to the "Points" line on the top to determine its number of points. Then, the total number of points from all five parameters is calculated (theoretical range: 0–200). Finally, the 1 and 2-year probabilities of MACE-free survival were calculated by drawing a vertical line from the "Total Points" line to the scales on the bottom two rows.

Diagnostic performance of the nomogram

We determined the discriminatory capacity of the model using receiver operating characteristic (ROC) analysis and calibration plots. In the development cohort, ROC analysis indicated the area-under-the-curve (AUC) was 0.790 (95% CI: 0.702–0.877) for prediction of 1-year MACE-free survival and the AUC was 0.802 (95% CI: 0.739–0.866) for prediction of 2-year MACE-free survival, suggesting the model had good predictive performance (Figures 4A,C). Moreover, internal validation using bootstrapping indicated the bias-corrected C-index was 0.750 for 1-year MACE-free survival and 0.774 for 2-year MACE-free survival. Analysis of the independent validation cohort indicated the AUC was 0.894 (95% CI: 0.802–0.967) for prediction of 1-year MACE-free survival and 0.798 (95% CI: 0.693–0.902) for prediction of 2-year MACE-free survival (Figures 4B,D).

We further analyzed these data using calibration plots to evaluate the consistency of the actual probabilities with
predicted probabilities for 1 and 2-year MACE-free survival in the development cohort (Figures 5A,C) and the external validation cohort (Figures 5B,D). We also used bootstrapping to determine the accuracy of the prediction model. In all cases, there were high correlations between the nomogram predictions and the actual observations.

We then applied DCA to determine the net benefit of the clinical prediction model (Figure 6). In the development cohort, the DCA results indicated that the threshold probability for prediction of MACE-free survival was 2–33% for 1-year MACE-free survival and 2–23% for 2-year MACE-free survival (Figures 6A,C). In the validation cohort, the DCA results indicated that the threshold probability for the prediction model was 5–38% for 1-year MACE-free survival and 5–64% for 2-year MACE-free survival (Figures 6B,D).

We used the total score of each patient in development cohort to stratify patients into a low-risk group (nomogram score < 120.01, n = 147), an intermediate-risk group (nomogram score = 120.01–133.72, n = 145), and a high-risk group (nomogram score > 133.72, n = 147) for analysis of 1 and 2-year MACE-free survival (Figures 6A,C). We used the same approach for the validation cohort (Figures 6B,D) and the overall cohort (Figures 6E,F).

Kaplan-Meier analysis of the development cohort (Figures 7A,C) with pairwise comparisons indicated that the risk of MACEs was greater in the high-risk group than the intermediate risk group at 1-year (χ² = 4.898, P = 0.027) and 2 years (χ² = 14.630, P < 0.001). Similarly, the high-risk group had a higher risk of MACEs than the low risk group at 1 year (χ² = 13.559, P < 0.001) and 2 years (χ² = 29.165, P < 0.001). Patients in the intermediate-risk group had a higher risk of MACEs than the low risk group at 1 year (χ² = 4.098, P = 0.043) and 2 years (χ² = 4.733, P = 0.030).

Kaplan-Meier analysis of data from the validation cohorts (Figures 7B,D) also indicated the high-risk group had a greater risk of MACEs than the intermediate-risk group at 1 year (χ² = 15.791, P < 0.001) and 2 years (χ² = 10.668, P = 0.001). Similarly, patients in the high-risk group had a greater risk of MACEs than the low-risk group at 1 year (χ² = 19.177, P < 0.001) and 2 years (χ² = 15.207, P < 0.001).

We also performed a Kaplan-Meier analysis of the overall study population (Figures 7E,F). Similar to the results above, patients in the high-risk group had a greater risk of MACEs than the intermediate-risk group at 1-year (χ² = 18.158, P < 0.001) and 2-years (χ² = 27.498, P < 0.001). Pairwise comparisons also indicated that the high-risk group had greater risk of MACEs.
than the low-risk group at 1-year ($\chi^2 = 27.711, P < 0.001$) and 2-years ($\chi^2 = 40.844, P < 0.001$).

**Discussion**

Our nomograms for predicting the 1 and 2-year probability of MACE-free survival in patients who had ACS used traditional clinical prognostic variables (age, diabetes, smoking, and previous myocardial infarction) and data from non-invasive ambulatory measurements (LF/HF ratio). Thus, we used routinely available clinical variables to develop a nomogram that had reliable discriminative ability, and we validated the nomogram model for predicting the risk of 1 and 2-year MACE-free survival. Our model has potential for use in the risk stratification of patients with ACS who received emergency coronary angiograms. It is possible that inclusion of other predictors in the future may further improve the model.

Acute coronary events may occur in patients who have none of the well-established classical cardiovascular risk factors, suggesting there may be additional coronary risk factors that have not yet been recognized (3–5, 10, 11). Therefore, systematic ACS risk-assessment tools and appropriate recommendations for risk assessment in clinical guidelines are essential for the implementation of strategies that prevent MACEs in these patients. There are several popular models for assessing the risk of cardiovascular disease, but they may not be suitable for use in all populations or countries (14). Moreover, established risk-assessment methods generally consider multiple blood markers, and the need for invasive examination may lead to delays in diagnosis and treatment. For example, the Global Registry of Acute Coronary Events (GRACE) score is widely accepted as a risk stratification tool for the prediction of in-hospital and 6-month all-cause mortality and myocardial infarction (20, 21). Nevertheless, clinicians have not yet optimized implementation of the GRACE score in the risk stratification for death and myocardial infarction at 12-months, particularly in ACS patients who receive standardized treatment (22, 23). Additionally, a retrospective cohort study of 3,982 ACS patients with non-ST-segment elevation found that incorporating available
clinical variables, including age, N-terminal pro-brain type natriuretic peptide, and serum creatinine, into a novel ABC score provided better predictions of long-term mortality after PCI than the GRACE score (24). However, the GRACE score and ABC score do not rely on home monitoring of cardiovascular health, a simple, non-invasive, and ambulatory monitoring technique. The use of wearable digital monitoring devices and of individualized risk assessment approaches is increasingly popular. Therefore, daily monitoring of the modulation of cardiac ANS via HRV analysis is a valuable, non-invasive, and easy-to-perform method that has relatively good reproducibility, and may provide useful information for the management of patients with ACS.

Our previous study of ACS patients found that automatic evaluation of cardiac ANS function was an effective method for risk-stratified prediction of MACEs when used with GRACE score, in that it provided accurate prognostic information and increased discriminatory ability (22). In addition, for individuals with no prior history of CAD, HRV analysis using remote digital technology may help to improve risk assessment by providing data over a long period of time that can complement classical cardiovascular risk factors. Our previous findings also indicated that HRV correlated with increased adverse cardiovascular events in patients with ACS (12, 25).

Endothelial injury results from the interaction between an imbalanced ANS and inflammation. Failure to maintain lipid homeostasis may result from endothelial injury, and lead to the activation of vascular smooth muscle cells and macrophage infiltration. These pathological events accelerate atherosclerotic plaque formation and cause the deterioration of myocardial ischemia (9, 10, 26, 27). Although an imbalanced ANS is a well-documented risk factor for adverse cardiovascular outcomes (12, 25, 28), few studies have evaluated the use of an integrated approach that incorporates HRV with classical factors for risk stratification. The Singapore Emergency Department Risk Stratification Model (SEDRSM) considers age, gender, heart rate, HRV parameters, and four 12-lead ECG variables to predict 30-day MACEs in patients who present to the emergency department with chest pain (13). However, the SEDRSM was not yet subjected to external validation, and therefore has limited value in clinical practice. Therefore, there is an urgent need for an inexpensive, simple, and non-invasive screening tool for patients with ACS who have a high risk of MACEs, especially for ACS patients who received standardized therapy protocols.

Our results indicated that it is currently simple and feasible to identify the risk of 1 and 2-year MACEs in patients with ACS. We also demonstrated favorable discriminative ability of the nomogram, based on the C-index and AUC values in the development and validation cohorts. Our internal validation (based on bootstrapping) and external validation also indicated the nomogram had satisfactory consistency in the prediction of MACEs. Our study therefore confirmed that specific clinical variables can be used for individualized predictions of risk and risk stratification for MACEs in patients with ACS. Our results may also contribute to the design and implementation of clinical trials that examine individualized clinical decision-making. Importantly, the rapid proliferation of wearable health technologies, such as smart wearable electronic devices that are equipped with green light-emitting diodes for photoplethysmography, for the self-monitoring of health-related parameters, including heart rate, heart-rate variability, and electrocardiograms, are now available in commercially available smartwatches and smartwatch accessories, with arrhythmia notification provided directly to the user (29–31). Thus, future studies could examine the use of smart wearable electronic devices that feature visual and personalized model-based risk assessment based on HRV and traditional risk factors. This may help ACS patients to receive dynamic real-time personalized treatment and management and reduce the high incidence of MACEs in these patients, even when they are at home.
FIGURE 7
Cumulative MACE-free survival of patients in different prognostic index (PI) tertiles. (A) Two year survival in the development cohort. (B) Two year survival in the external validation cohort. (C) One year survival the development cohort. (D) One year survival the external validation cohort. (E) One year survival in the complete cohort. (F) Two year survival in the complete cohort. Central illustration: Smart wearable electronic devices that use visual and personalized model-based risk assessment and an integrated approach that considers heart rate variability and clinical data (traditional risk factors) could allow patients to receive 24-h real-time personalized home telemonitoring and receive improved clinical management.

Study limitations

It is important to note that while our model has significant promise for predicting MACEs in ACS patients who received emergency coronary angiography, there were a few limitations. First, because the sample size was relatively small, the predictive ability of the model needs to be confirmed in large prospective cohort studies. Second, due to the retrospective nature of this study, detailed patient information, such as the GRACE score and the time of ACS onset, was not recorded. Third, although we accounted for several known confounding factors, some unknown confounding factors may have remained that affected HRV. Four, because the two hospitals used different methods for measuring troponin and creatine kinase isoenzyme MB, we
did not include these variables in the analysis. Five, because this study was observational, it is unknown if better outcomes could have been achieved from the use of individualized and comprehensive treatment based on other ANS risk models. Six, additional indicators of ANS, such as deceleration capacity, may be also useful as prognostic indicators. Future studies are therefore needed to assess the validity and accuracy of point-of-care testing of cardiac ANS in predicting MACEs after ACS. Finally, for methodological reasons, the ANS can only be assessed using HRV in patients with a sinus rhythm, and the impact of a non-sinus rhythm in patients with ACS remains uncertain.

Conclusion

Our observational study demonstrated that a risk nomogram that incorporated four conventional clinical characteristics and a single ANS parameter (LF/HF) was a simple method that clinicians can use to assess the risk of MACEs in patients with ACS. We suggest that future large studies are needed for further validation of our nomogram. Nonetheless, the results indicated that our nomogram appeared to be useful for identifying risk of MACEs in patients with ACS, and thus provide a foundation for the use of mobile health monitoring based on alterations of the ANS.

Data availability statement

Individual participant data that underlie the results reported in this article, after de-identification can be obtained from the corresponding authors upon reasonable request.

Ethics statement

The studies involving human participants were reviewed, approved and granted for the study by the Local Ethics Committee (Renmin Hospital of Wuhan University; No. WDRY2022-K075; Xiangyang Central Hospital; No.2022-066). The ethics committee waived the requirement of written informed consent for participation.

Author contributions

HJ, XZ, and HF conceived and performed the experiments. JW and JS performed the experiments and wrote the manuscript. XW and TZ provided expertise and feedback. TX, FY, SD, QD, ZL, FG, XL, YW, and LS provided valuable suggestions and edited the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the grants from the National Natural Science Foundation of China (grant no. 81970287).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1053470/full#supplementary-material

References

1. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. (2019) 393:1958–72.

2. He Y, Li Y, Yang X, Hemler EC, Fang Y, Zhao L, et al. The dietary transition and its association with cardiometabolic mortality among Chinese adults, 1982-2012: a cross-sectional population-based study. Lancet Diabetes Endocrinol. (2019) 7:540–8. doi: 10.1016/S2213-8587(19)30152-4

3. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. (2003) 290:898–904. doi: 10.1001/jama.290.7.898

4. Askin L, Duman H, Ozylidiz A, Tanriverdi O. Association of serum chemerin levels with coronary artery disease: pathogenesis and clinical research. Cardiovasc Innov Appl. (2019) 4:251–6. doi: 10.15212/CVIA.2019.0572
5. Han Z, Lai L, Pu Z, Yang L. A nomogram to predict patients with obstructive coronary artery disease: development and validation. Cardiovasc Innov Appl. (2021) 5:245–55. doi: 10.15212/CTIA.2021.0001

6. Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life’s essential 8: updating and enhancing the American heart association’s construct of cardiovascular health: a presidential advisory from the American heart association. Circulation. (2022) 146:e1–43. doi: 10.1161/CIR.0000000000001078

7. Lloyd-Jones DM, Ning H, Labarthe D, Brewer L, Sharma G, Rosamond W, et al. Status of cardiovascular health in us adults and children using the American heart association’s new ‘life’s essential 8’ metrics: prevalence estimates from the national health and nutrition examination survey (NHANES), 2013-2018. American heart association’s new “life’s essential 8” metrics: prevalence estimates W, et al. Status of cardiovascular health in US adults and children using the American heart association’s new “life’s essential 8” metrics: prevalence estimates from the national health and nutrition examination survey (NHANES), 2013–2018. Circulation. (2022) 146:822–35. doi: 10.1161/CIRCULATIONAHA.122.060911

8. Falter M, Budts W, Goetschalckx K, Cornelissen V, Buys R. Accuracy of apple watch measurements for heart rate and energy expenditure in patients with cardiovascular disease: cross-sectional study. JAMA. (2022) 327:1189. doi: 10.1001/jama.2021.11899

9. Mohanta SK, Peng L, Li Y, Lu S, Sun T, Carnevale L, et al. Neuroimmunology and cardiovascular interfaces control atherosclerosis. Nature. (2022) 7908:152–9. doi: 10.1038/s41586-022-04673-6

10. Wang J, Liu W, Chen H, Liu C, Wang M, Chen H, et al. Novel insights into the interaction between the autonomic nervous system and inflammation on coronary physiology: a quantitative flow ratio study. Front Cardiovasc Med. (2022) 9:700943. doi: 10.3389/fcvm.2021.700943

11. Wang J, Liu C, Guo F, Zhou Z, Zhou L, Wang Y, et al. Deceleration capacity improves prognostic accuracy of relative increase and final coronary physiology in patients with non-ST-elevation acute coronary syndrome. Front Cardiovasc Med. (2022) 9:848499. doi: 10.3389/fcvm.2022.848499

12. Xhyrii B, Manfrini O, Mazzolini M, Pizzi C, Bugiardini R. Heart rate variability today. Preg Cardiovasc Dis. (2012) 55:321–31. doi: 10.1016/j.pcad.2012.09.001

13. Heldeweg ML, Liu N, Koh ZX, Fook-Chong S, Lye WK, Harms M, et al. A novel cardiovascular risk stratification model incorporating ECG and heart rate variability for patients presenting to the emergency department with chest pain. Crit Care. (2016) 20:179. doi: 10.1186/s13054-016-1367-5

14. Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol. (2015) 5:301–11. doi: 10.1038/nrcardio.2015.28

15. Blatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. (1970) 7:662–75. doi: 10.1001/jama.2022.0358

16. Taralov ZZ, Terziyski KV, Kostianev SS. Heart rate variability as a method for assessment of the autonomic nervous system and the adaptations to different physiological and pathological conditions. Folia Med. (1970) 57:173–80. doi: 10.1515/folmed.2015-0036

17. Catai AM, Pastre CM, Godoy MF, Silva ED, Takahashi ACM, Vanderlei LCM. Heart rate variability: are you using it properly? Standardisation checklist of procedures. Braz J Phys Ther. (2020) 2:91–102. doi: 10.1267/bjpt.2019.02.006

18. Voss A, Schroeder R, Välverud M, Schulz S, Cygankiewicz I, Vázquez R, et al. Short-term vs. long-term heart rate variability in ischemic cardiomyopathy risk stratification. Front Physiol. (2013) 4:364. doi: 10.3389/fphys.2013.00364

19. Latti S, Niinimäe M, Pentikainen OT, Rocker: open source, easy-to-use tool for AUC and enrichment calculations and ROC visualization. J Cheminform. (2016) 8:45. doi: 10.1186/s13321-016-0158-v

20. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. (2006) 333:1091. doi: 10.1136/bmj.38985.646481.55

21. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. (2004) 291:2727–33. doi: 10.1001/jama.291.22.2727

22. Duan S, Wang J, Yu F, Song L, Liu C, Sun J, et al. Enrichment of the postdischarge grace score with deceleration capacity enhances the prediction accuracy of the long-term prognosis after acute coronary syndrome. Front Cardiovasc Med. (2022) 9:888753. doi: 10.3389/fcvm.2022.888753

23. Chew DP, Hyun K, Morton E, Horsfall M, Hills GS, Chow CK, et al. Objective risk assessment vs standard care for acute coronary syndromes: a randomized clinical trial. JAMA Cardiol. (2021) 6:304–13. doi: 10.1001/jamacardio.2020.6314

24. Zheng YY, Wu TT, Gao Y, Guo QQ, Ma YY, Zhang JC, et al. A novel abc score predicts mortality in non-st-segment elevation acute coronary syndrome patients who underwent percutaneous coronary intervention. Thorac Heartv. (2021) 121:297–308. doi: 10.1055/s-0040-178411

25. Brateaun A. Heart rate variability after myocardial infarction: what we know and what we still need to find out. Curr Med Res Opin. (2015) 10:1855–60. doi: 10.1185/03007995.2015.106066

26. Münnel T, Schmidt JP, Steven S, Herzog J, Däuber A, Sorensen M. Environmental noise and the cardiovascular system. J Am Coll Cardiol. (2018) 71:688–97. doi: 10.1016/j.jacc.2017.12.015

27. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. (2012) 487:325–9. doi: 10.1038/nature11260

28. Yu L, Huang B, Po SS, Tan T, Wang M, Zhou L, et al. Low-level tragus stimulation for the treatment of ischemia and reperfusion injury in patients with ST-segment elevation myocardial infarction: a proof-of-concept study. JACC Cardiovasc Interv. (2017) 10:1511–20. doi: 10.1016/j.jcin.2017.04.036

29. Raja JM, Elskar C, Roman S, Cave B, Pour-Ghaz I, Nanda A, et al. Apple watch, wearables, and heart rhythm: where do we stand? Ann Transl Med. (2019) 7:1417. doi: 10.21037/atm.2019.06.79

30. Turakhia MP, Desai M, Hedlin H, Rajmani A, Talati N, Ferris T, et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the apple heart study. Am Heart J. (2019) 207:66–75. doi: 10.1016/j.ahj.2018.09.002

31. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. (2019) 381:1909–17. doi: 10.1056/NEJMoa1901183